CN102670689A - Method for preparing spray for curing psoriasis - Google Patents
Method for preparing spray for curing psoriasis Download PDFInfo
- Publication number
- CN102670689A CN102670689A CN2011100602549A CN201110060254A CN102670689A CN 102670689 A CN102670689 A CN 102670689A CN 2011100602549 A CN2011100602549 A CN 2011100602549A CN 201110060254 A CN201110060254 A CN 201110060254A CN 102670689 A CN102670689 A CN 102670689A
- Authority
- CN
- China
- Prior art keywords
- boswellic acid
- acid
- spray
- dehydrogenation
- acetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a method for preparing a spray for curing psoriasis. A main drug is extracted from natural plants, the main drug is dispersed in a liquid dispersion medium, a transdermal enhancer is added, uniformly stirring and mixing are preformed, and sterilization and filling are further performed to obtain the spray for curing psoriasis. The spray is used for curing psoriasis of various types and has the advantages that the usage is convenient, the curative effect is remarkable, the drug targeting is high, and the like. The spray is capable of effectively relieving and curing symptoms of a patient, and further the relapse is not prone to occur after the patient is cured.
Description
Technical field
The invention belongs to technical field of medicine, be specifically related to treat the psoriasis spray preparing process.
Background technology
Psoriasis is commonly called as psoriasis; It is a kind of erythroderma desquamativum of common easy relapse; Mainly be divided into psoriasis vulgaris, pustule psoriasis pustulosa, psoriasis arthropathica and erythrodermic psoriasis; It is numerous that it causes reason, thinks mostly that in recent years heredity, dysbolismus, infection, immune dysfunction etc. possibly be pathogenic factor, and seasonal variations, humidity, psychic trauma or operation etc. possibly cause psoriasis.Make a general survey of the history of psoriasis Drug therapy; Mustard gas ointment, procaine block, the autohemotherapy of the former Soviet Union learnt by China from the 1950's; The Bai Xuening of the sixties is to the ethyliminum of the seventies, the bimolane of the eighties; Most drug or not obvious because of its curative effect or is eliminated because of its erious adverse reaction.General treatement can only be freed one's mind of misgivings, and eliminates psychic trauma, avoids various risk factors, at present psoriasis is not still had the medicine of radical cure, and existing medicine can only reach short term effect, can not prevent recurrence.According to investigations, psoriasis has influence on 2%～3% total population, is one of the most common autoimmune disease in the whole world, and maybe be relevant with other diseases associated with inflammation such as psoriatic arthritis, inflammatory bowel and coronary artery disease etc.The annual a large amount of foreign exchange of cost that needs of China is used for import treatment psoriasis medicine, and the treatment psoriasis medicine of therefore researching and developing China's independent intellectual property right is imperative.The research of applicant team shows: compare with normal person's skin, the overactivity of psoriatic's epidermis and intradermal transcribed nucleic acid factor NF-kappa B can cause a large amount of releases of the TNF-alpha factor, and this reason has been brought out human psoriasis just.
In order to overcome the problem that present treatment psoriasis medicine exists, the invention provides a kind of treatment psoriasis spray preparing process.The principal agent composition of this medicine is the effective ingredient that extracts from natural plants; Side effect is little, production cost is low, targeting property is strong; And can selectivity suppress the overexpression of transcribed nucleic acid factor NF-kappa-B; Thereby suppress a large amount of releases of the TNF-alpha factor, reach inhibition and treat psoriatic purpose.
Summary of the invention
The purpose of this invention is to provide a kind of treatment psoriasis spray; Wherein the principal agent composition is the effective ingredient that extracts from natural plants; Production cost is low, side effect is little, targeting property is strong; And can suppress the overexpression of transcribed nucleic acid factor NF-kappa-B by selectivity, thereby suppress a large amount of releases of the TNF-alpha factor, reach inhibition and treat psoriatic purpose.
A kind of its raw material components and weight proportion of treating the psoriasis spray of the present invention can be:
Principal agent 0.1wt%～25wt%
Transdermal enhancer 0.5wt%～30wt%
Liquid dispersion medium 30wt%～80wt%
Preferably; Described treatment psoriasis spray; It is characterized in that described principal agent is by the a-boswellic acid that from Olibanum, extracts, a-acetyl boswellic acid, beta boswellic acid, β-acetyl boswellic acid, 11-carbonyl-beta boswellic acid, 11-carbonyl-beta-acetyl boswellic acid, 9,11-dehydrogenation-a-boswellic acid, 9,11-dehydrogenation-a-acetyl boswellic acid, 9; 11-dehydrogenation-beta boswellic acid, 9, one or more compositions in boswellic acid such as 11-dehydrogenation-β-acetyl boswellic acid and the derivant thereof; Described transdermal enhancer is by one or more compositions in azone, dimethyl sulfoxide, decyl methyl sulfoxide, 1,3 propylene glycol, menthol, Borneolum Syntheticum, Oleum Caryophylli, lauric acid, oleic acid, the almond oil; Described liquid dispersion medium is made up of in water, ethanol, glycerin, Polyethylene Glycol, formal glycerine, dimethyl acetylamide and the N-Methyl pyrrolidone etc. one or more.
Another object of the present invention provides a kind of treatment psoriasis spray preparing process, is about to principal agent and is dispersed in the liquid dispersion medium, adds transdermal enhancer, after mixing, and sterilization, fill, packing makes.
Preferably; Described treatment psoriasis spray preparing process; It is characterized in that described principal agent is by the a-boswellic acid that from Olibanum, extracts, a-acetyl boswellic acid, beta boswellic acid, β-acetyl boswellic acid, 11-carbonyl-beta boswellic acid, 11-carbonyl-beta-acetyl boswellic acid, 9,11-dehydrogenation-a-boswellic acid, 9,11-dehydrogenation-a-acetyl boswellic acid, 9; 11-dehydrogenation-beta boswellic acid, 9, one or more compositions in boswellic acid such as 11-dehydrogenation-β-acetyl boswellic acid and the derivant thereof; Described liquid dispersion medium is by a kind of or multiple composition the in water, ethanol, glycerin, Polyethylene Glycol, formal glycerine, dimethyl acetylamide and the N-Methyl pyrrolidone etc.; Described transdermal enhancer is by one or more compositions in azone, dimethyl sulfoxide, decyl methyl sulfoxide, 1,3 propylene glycol, menthol, Borneolum Syntheticum, Oleum Caryophylli, lauric acid, oleic acid, the almond oil.
Treatment psoriasis spray of the present invention is through repeatedly experimentation; The preferred proportional quantity of liquid dispersion medium, transdermal enhancer and principal agent; The interval of processing step and various heating-up temperatures makes the dissolubility of principal agent reach higher level, and has increased stability of drug.Technological process and control Rational Parameters have easy, steady quality, the characteristics that production efficiency is high controlled.This spray is used to treat various types of psoriasises, all has advantages such as easy to use, evident in efficacy, that drug targeting property is strong.
The specific embodiment
Below in conjunction with specific embodiment such scheme is further specified.Should be understood that these embodiment are used to the present invention is described and are not limited to limit scope of the present invention.
Embodiment 1
Take by weighing principal agent 11-carbonyl-beta-acetyl boswellic acid 150 grams, liquid dispersion medium ethanol 400 grams, transdermal enhancer azone 50 grams, almond oil 40 grams, Borneolum Syntheticum 10 grams add water to 1000 grams, mix, and it is qualified that semi-finished product detect, sterilization, fill promptly gets.
Embodiment 2
Take by weighing principal agent a-boswellic acid 190 grams, liquid dispersion medium propylene glycol 600 grams, transdermal enhancer lauric acid 80 grams add water to 1000 grams, mix, and it is qualified that semi-finished product detect, sterilization, fill promptly gets.
Embodiment 3
Take by weighing principal agent beta boswellic acid 100 grams, liquid dispersion medium formal glycerine 700 grams, transdermal enhancer menthol 60 grams add water to 1000 grams, mix, and it is qualified that semi-finished product detect, sterilization, fill promptly gets.
Embodiment 4
Take by weighing principal agent: a-boswellic acid 10 grams, β-acetyl boswellic acid 15 grams, 11-carbonyl-beta boswellic acid 53 grams, 11-carbonyl-beta-acetyl boswellic acid 20 grams, 9,11-dehydrogenation-a-boswellic acid 10 grams, 9,11-dehydrogenation-a-acetyl boswellic acid 10 grams, 9; 11-dehydrogenation-beta boswellic acid 20 grams, 9,11-dehydrogenation-β-acetyl boswellic acid 30 grams, liquid dispersion medium al glycerol 60 grams, dimethyl acetylamide 40 grams and N-Methyl pyrrolidone 500 grams; Transdermal enhancer oleic acid 30 grams, almond oil 40 grams; Add water to 1000 grams, mix, it is qualified that semi-finished product detect; Sterilization, fill promptly gets.
Embodiment 5 carries out the test of following animal acute toxicity test and general pharmacology, to prove the safety of medicine according to the invention in order further to understand this medicine.
Animal acute toxicity test
The treatment psoriasis spray that will make by method provided by the present invention; Through the mouse back administration: when finding to adopt 30 milligrams/kilogram of principal agents (be equivalent to clinical RD 430 times); Toxic reaction and death do not occur, prove that this spray does not have acute toxicity to mice.
The general pharmacology test
Adopt Beagle dog, KM mice and ICR mice that this spray is carried out general pharmacology and learn research.
Spray outside the Beagle dog back principal agent branch account for low (3 milligrams/kilogram), in this spray and the distilled water (control experiment) of (10 milligrams/kilogram), high (20 milligrams/kilogram) three dosage, totally 4 groups are observed cardiovascular system, respiratory system.
Mouse back spray outward the principal agent branch account for low (3 milligrams/kilogram), in this spray and the distilled water (control experiment) of (10 milligrams/kilogram), high (20 milligrams/kilogram) three dosage; Totally 4 groups are observed (spontaneous activity counting, pole-jump test and the effect of sub-threshold dose pentobarbital sodium hypnosis Synergism Testing) to nervous system.
The result: this spray does not all have obvious influence to the P wave voltage of Beagle dog systolic pressure, diastolic pressure, mean arterial pressure, heart rate, the rhythm of the heart, ECG, T wave voltage, QRS time, PR interval, QT interval, ST section, respiratory frequency, the rhythm and pace of moving things and amplitude.This spray does not have obvious influence to spontaneous activity in mice, pole-climbing ability, and hypnosis does not have synergism to the sub-threshold dose pentobarbital sodium.
The result shows that this spray does not have obvious influence to Beagle dog cardiovascular system, respiratory system, and the mice nervous system is not had obvious influence, explains that these article have good safety.
The beneficial effect that clinical application research below the embodiment 6 and conclusion further illustrate medicament spraying agent of the present invention.
Test is selected into 14～45 years old psoriatic of 10 examples altogether.The patient goes to a doctor and did not use any oral and external medication in previous month.The equal external psoriasis of patient medicament spraying agent, after 1 month, observing effect.The patient all has no adverse reaction, and after the treatment remarkable result is arranged.
Typical case
Li patient, male, 30 years old.
Before the prescription on individual diagnosis, showed effect repeatedly 2 years, erythra shows as skin of back and flushing occurs, and whole body presents the diffusivity flushing and soaks into, and morbidity every day, a large amount of squamas came off, heating, and headache is diagnosed as erythrodermic psoriasis.Go to a doctor in preceding 1 month to using any oral or medicine for external use treatment.Give psoriasis medicament spraying agent external curing, spray skin lesion place, each is used once sooner or later, observing effect after 10 days, the skin lesion site color is obviously thin out, and heating, headache disappear.After continuing medication to 3 week, the skin lesion site color continues to subtract light, and it is normal that skin recovers gradually.To 6 all further consultations, it is normal that skin recovers.This routine patient's therapeutic evaluation is for curing.Part and systemic adverse reactions do not appear during the medication.
Above-mentioned instance only is explanation technical conceive of the present invention and characteristics, and its purpose is to let the people who is familiar with this technology can understand content of the present invention and enforcement according to this, can not limit protection scope of the present invention with this.All equivalent transformations that spirit is done according to the present invention or modification all should be encompassed within protection scope of the present invention.
Claims (7)
1. treat the psoriasis spray; It is characterized in that composition comprises principal agent, transdermal enhancer and liquid dispersion medium in the spray; Wherein principal agent is a natural plant extracts; Can effectively suppress psoriatic's epidermis and the overactivity of intradermal transcribed nucleic acid factor NF-kappa B, thereby reach control, suppress and treat psoriatic purpose.
2. treatment psoriasis spray according to claim 1; It is characterized in that described principal agent is by the effective ingredient that from natural plants, extracts; Like a-boswellic acid, a-acetyl boswellic acid, beta boswellic acid, β-acetyl boswellic acid, 11-carbonyl-beta boswellic acid, the 11-carbonyl-beta-acetyl boswellic acid, 9 that extracts in the Olibanum; 11-dehydrogenation-a-boswellic acid, 9,11-dehydrogenation-a-acetyl boswellic acid, 9,11-dehydrogenation-beta boswellic acid, 9; One or more compositions in boswellic acid such as 11-dehydrogenation-β-acetyl boswellic acid and the derivant thereof, content is 0.1wt%～25wt%.
3. treatment psoriasis spray according to claim 1; It is characterized in that described transdermal enhancer is by azone, dimethyl sulfoxide, decyl methyl sulfoxide, 1; One or more compositions in 3 propylene glycol, menthol, Borneolum Syntheticum, Oleum Caryophylli, lauric acid, oleic acid, the almond oil, content are 0.5wt%～30wt%.
4. treatment psoriasis spray according to claim 1; It is characterized in that described liquid dispersion medium is made up of in water, ethanol, glycerin, Polyethylene Glycol, formal glycerine, dimethyl acetylamide and the N-Methyl pyrrolidone etc. one or more, content is 30wt%～80wt%.
5. treatment psoriasis spray according to claim 1 is characterized in that can being used to treat psoriasis, requires this characteristic is classified as the claim scope.
6. treatment psoriasis spray according to claim 1 is characterized in that described method for preparing is: principal agent is dispersed in the liquid dispersion medium, adds transdermal enhancer, and after mixing, sterilization, fill, packing both got.
7. treatment psoriasis spray preparing process according to claim 6; Its characteristic at described principal agent by the effective ingredient that from natural plants, extracts; Like a-boswellic acid, a-acetyl boswellic acid, beta boswellic acid, β-acetyl boswellic acid, 11-carbonyl-beta boswellic acid, the 11-carbonyl-beta-acetyl boswellic acid, 9 that extracts in the Olibanum; 11-dehydrogenation-a-boswellic acid, 9; 11-dehydrogenation-a-acetyl boswellic acid, 9,11-dehydrogenation-beta boswellic acid, 9, one or more compositions in boswellic acid such as 11-dehydrogenation-β-acetyl boswellic acid and the derivant thereof; Described liquid dispersion medium is made up of in water, ethanol, glycerin, Polyethylene Glycol, formal glycerine, dimethyl acetylamide and the N-Methyl pyrrolidone etc. one or more; Described transdermal enhancer is by one or more compositions in azone, dimethyl sulfoxide, decyl methyl sulfoxide, 1,3 propylene glycol, menthol, Borneolum Syntheticum, Oleum Caryophylli, lauric acid, oleic acid, the almond oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100602549A CN102670689A (en) | 2011-03-14 | 2011-03-14 | Method for preparing spray for curing psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100602549A CN102670689A (en) | 2011-03-14 | 2011-03-14 | Method for preparing spray for curing psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102670689A true CN102670689A (en) | 2012-09-19 |
Family
ID=46803675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100602549A Pending CN102670689A (en) | 2011-03-14 | 2011-03-14 | Method for preparing spray for curing psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102670689A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070913A (en) * | 2012-11-30 | 2013-05-01 | 甘肃中医学院 | Penetration enhancer composition and application of penetration enhancer composition in permeation enhancement |
| CN108888618A (en) * | 2018-06-21 | 2018-11-27 | 上海交通大学医学院 | Newtype drug and its application for treating psoriasis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368277A (en) * | 2001-02-06 | 2002-09-11 | 杨孟君 | Nano medicine 'Yujin Yinxie' and its preparing process |
| WO2003099302A1 (en) * | 2002-05-24 | 2003-12-04 | Turispharma S.R.L. | A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere |
| CN1621079A (en) * | 2003-11-26 | 2005-06-01 | 许力法 | Chinese traditional medicine for treating psoriasis and cutaneous pruritus |
-
2011
- 2011-03-14 CN CN2011100602549A patent/CN102670689A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368277A (en) * | 2001-02-06 | 2002-09-11 | 杨孟君 | Nano medicine 'Yujin Yinxie' and its preparing process |
| WO2003099302A1 (en) * | 2002-05-24 | 2003-12-04 | Turispharma S.R.L. | A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere |
| CN1621079A (en) * | 2003-11-26 | 2005-06-01 | 许力法 | Chinese traditional medicine for treating psoriasis and cutaneous pruritus |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070913A (en) * | 2012-11-30 | 2013-05-01 | 甘肃中医学院 | Penetration enhancer composition and application of penetration enhancer composition in permeation enhancement |
| CN103070913B (en) * | 2012-11-30 | 2015-06-24 | 甘肃中医学院 | Penetration enhancer composition and application of penetration enhancer composition in permeation enhancement |
| CN108888618A (en) * | 2018-06-21 | 2018-11-27 | 上海交通大学医学院 | Newtype drug and its application for treating psoriasis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Emamuzo et al. | Analgesic and anti—inflammatory activities of the ethanol extract of the leaves of Helianthus Annus in Wistar rats | |
| CN110169961B (en) | Exercise rehabilitation compound essential oil | |
| CN102670689A (en) | Method for preparing spray for curing psoriasis | |
| CN101612290B (en) | Medicinal composition for treating burn and scald and preparation method thereof | |
| CN101259149A (en) | Tinctura for treating beriberi | |
| CN101579423B (en) | Medicament composition for treating beriberi and preparation method thereof | |
| CN103768388A (en) | Traditional Chinese medicine formula for treating scalds, burns and trauma by being singly applied externally | |
| CN102106920B (en) | Chinese medicinal composition for treating burn and scald and application thereof | |
| CN101843801A (en) | Bone permeable blood-activating and pain-relieving tincture | |
| CN110013502A (en) | A kind of composition for preventing and treating acute and chronic rhinitis, nasosinusitis | |
| CN106727542A (en) | Application of the jamaicin in the medicine for preparing treatment acute soft tissue injury | |
| CN106266453A (en) | A kind of composition for external application and application thereof | |
| CN102716225A (en) | Externally dressed drug for treating burns and scalds | |
| CN102920800B (en) | Topical drug composite and application and preparation method thereof | |
| CN104510955A (en) | Traditional Chinese medicine formula for treating beriberi | |
| CN105902722B (en) | Traditional Chinese medicine composition for treating leucoderma as well as preparation method and application thereof | |
| CN108653431A (en) | Prevent pharmaceutical composition, preparation method and applications and the preparation of rhinitis | |
| CN116327828B (en) | Lithospermum and peony seed oil spray film for light and medium burns and scalds and preparation method thereof | |
| CN102824511A (en) | Miao medicine used for oralcavity and preparation technology | |
| CN101396495B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease | |
| CN1177601C (en) | Medicine for treating scald | |
| CN107693612A (en) | A kind of antipsoriatics cream | |
| CN102210736B (en) | Medicine composition for treating tenosynovitis and preparation method thereof | |
| CN115337359A (en) | External traditional Chinese medicine composition for treating mite dermatitis and preparation method thereof | |
| CN112121062A (en) | External-use medicine composition for treating bromhidrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120919 |